Skip to content

Observe the clinical efficacy of Shenqi Dihuang Decoction in treating Qi-Yin deficiency syndrome of type 2 diabetic nephropathy and its influence on biomarkers related to ferroptosis

Observe the clinical efficacy of Shenqi Dihuang Decoction in treating Qi-Yin deficiency syndrome of type 2 diabetic nephropathy and its influence on biomarkers related to ferroptosis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074000
Enrollment
Unknown
Registered
2023-07-27
Start date
2023-07-27
Completion date
Unknown
Last updated
2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

Shenqi Dihuang decoction Group:SGLT-2 basic hypoglycemic treatment + Shenqi Dihuang Decoction, SGLT-2 once a day, one tablet each time, Shenqi Dihuang decoction twice in the morning and evening, 200ml
Control group:SGLT-2 basic hypoglycemic treatment

Sponsors

Kunshan Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Consistent with the diagnostic criteria for type 2 diabetes; (2) Consistent with the diagnosis of diabetic nephropathy; (3) Be between 18 and 75 years old; (4) Consistent with the diagnostic criteria of Qi-Yin injury; (5) The patient has informed consent and is willing to accept the corresponding treatment.

Exclusion criteria

Exclusion criteria: (1) Patients with acute diabetic complications such as diabetic ketoacidosis; (2) Patients with acute injury stress such as infection, shock, bleeding, severe dehydration, burn, etc. (3) Patients with malignant tumors and serious heart, liver, brain and kidney diseases; (4) Pregnant and lactating women; (5) People with primary kidney disease or secondary kidney disease for other reasons; (6) Patients with immune system diseases such as connective tissue diseases and rheumatic diseases; ? Allergic to or contraindicated with the drugs related to this study; (8) Use of GLP-1 Ra or DPP-4 inhibitors in the last three months; (9) Participants who are participating in or within 4 weeks of another clinical trial; (10) Cognitive impairment or poor compliance, inability to follow up, or mental illness.

Design outcomes

Primary

MeasureTime frame
Urinary albumin creatinine ratio;

Secondary

MeasureTime frame
Ferritin;Free iron;Transferrin;Ceruloplasmin;Glutathione peroxidase GPX4;Malondialdehyde MDA;Acyl-coa synthetase Long Chain Family Member 4 (ACSL4);

Countries

China

Contacts

Public ContactYuqiong Chen

Kunshan Hospital of Traditional Chinese Medicine

1327386047@qq.com+86 152 9551 8790

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026